Roche's Genentech will acquire a portfolio of next-generation CDK inhibitors from Regor Pharmaceuticals for the treatment of breast cancer.
Per the deal, Regor, which has headquarters in both Boston and Shanghai, will receive an upfront cash payment of $850 million and is eligible to receive additional cash payments based on certain predetermined milestones. Genentech will be responsible for clinical development, manufacturing and commercialization worldwide. Regor will continue to manage the two ongoing phase 1 trials to their completion.
Key to the deal is Regor's most advanced orally-administered CDK4/2 inhibitor in the clinic, RGT-419B, which has demonstrated best-in-class potential as next-gen CDKi in in hormone receptor-positive breast cancer. A potent CDK4 inhibitor with increased activity on CDK2 addressing a key mechanism of resistance to existing therapies, RGT-419B is slated for phase 2 trials next year. In late 2023, Regor shared promising safety and single agent efficacy data evaluating RGT-419B in HR+/HER2- advanced breast cancer patients who have progressed on CDK4/6 Inhibitors and endocrine therapy.
Also included in the deal — announced during Roche Pharma Day 2024 — is RGT-587, a phase 1-ready brain-penetrant selective CDK4i.